Biopharmaceutical Manufacturing: An Evolving Industry
Received Date: Jul 01, 2022 / Accepted Date: Jul 28, 2022 / Published Date: Jul 28, 2022
Abstract
The biopharmaceutical assiduity is evolving with a shift in focus from recombinant proteins and antibodies towards more complex cell and gene curatives. To be competitive encyclopaedically, bio manufacturers need to concentrate on aligning with global norms with regard to medicine quality, reducing manufacturing failures and delivering medicines to vend snappily. Erecting these capabilities requires a multifaceted approach that includes advancements in operations, quality compliance, and control strategies. To address these requirements, the US Pharmacopeia (USP), the Department of Biotechnology (DBT) India, and the Confederation of Indian Industry (CII) held a council to bandy the conditions and gaps in the biotechnology and pharmaceutical sectors in India and other developing countries.
Citation: Uchizono JA (2022) Biopharmaceutical Manufacturing: An Evolving Industry. Clin Pharmacol Biopharm, 11: 277. Doi: 10.4172/2167-065X.1000277
Copyright: © 2022 Uchizono JA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
Recommended Journals
91勛圖 Journals
Article Tools
Article Usage
- Total views: 2375
- [From(publication date): 0-2022 - Aug 29, 2025]
- Breakdown by view type
- HTML page views: 1978
- PDF downloads: 397
